Clinical Trial

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2025-10-17; most recent amendment 2026-04-07.
Status change: Not Yet Recruiting → Recruiting 2025-11-07
Trial Details
NCT Number NCT07219511
Lead Sponsor Vasa Therapeutics
Conditions Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
Enrollment 42 participants
Start Date 2025-11-04
Primary Completion 2026-06 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-09